ArticleJournal of Korean medical science2026
Comparative Renal Safety of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A Korean Nationwide Study.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe long-term renal safety of tenofovir-based therapy in patients with chronic hepatitis B virus (HBV) infection remains uncertain, particularly regarding end-stage kidney disease requiring renal replacement therapy (RRT). We investigated the comparative risk of renal dysfunction between tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF).
methodsWe identified treatment-naïve adult patients with chronic HBV infection who initiated TAF or TDF between 2017 and 2020 from the Korean National Health Insurance Service. After 1:1 propensity score (PS) matching, we compared the incidence of RRT and chronic kidney disease (CKD) between the two groups.
resultsAmong 46,663 eligible patients (TAF, n = 16,885; TDF, n = 29,778), the median follow-up was 2.61 years. The incidence of RRT were 0.56 and 0.96 per 1,000 person-years in the TAF and TDF groups, respectively (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.47-1.16). In the PS-matched cohort (n = 31,218), the adjusted HR for RRT was 0.67 (95% CI, 0.40-1.10) in TAF compared to TDF. Male sex, older age, hypertension, cirrhosis and current smoking were associated with the increased risk of RRT.
conclusionIn this nationwide claims-based cohort, TAF and TDF showed comparable renal safety with respect to RRT and the development of CKD. Male sex, older age, hypertension, and liver cirrhosis were associated with increased renal risk and warrant close monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.